Table 2. Univariate Cox proportional regression analysis on overall and disease-specific 5-year survival of 259 primary melanoma patients.
| Variable | Patients (%) | Overall survival | Disease-specific survival | ||||||
| Deaths | Death Rate | HR (95% CI) | P † | Deaths | Death Rate | HR (95% CI) | P † | ||
| Age | |||||||||
| ≤60 | 124 (47.9%) | 21 | 16.9% | 2.65 (1.58–4.42) | <0.001 | 21 | 16.9% | 2.14 (1.26–3.65) | 0.005 |
| >60 | 135 (52.1%) | 48 | 35.6% | 39 | 28.9% | ||||
| Sex | |||||||||
| Male | 138 (53.3%) | 37 | 26.8% | 1.00 (0.62–1.61) | 0.994 | 34 | 24.6% | 0.89 (0.53–1.48) | 0.645 |
| Female | 121 (46.7%) | 32 | 26.4% | 26 | 21.5% | ||||
| Thickness (mm) | |||||||||
| ≤2.00 | 152 (58.7%) | 22 | 14.5% | 4.32 (2.60–7.19) | <0.001 | 17 | 11.2% | 5.09 (2.89–8.94) | <0.001 |
| >2.00 | 107 (41.3%) | 47 | 43.9% | 43 | 40.2% | ||||
| Ulceration | |||||||||
| Absent | 211 (85.3%) | 42 | 19.9% | 4.64 (2.84–7.59) | <0.001 | 37 | 17.5% | 4.43 (2.61–7.51) | <0.001 |
| Present | 48 (14.7%) | 27 | 56.3% | 23 | 47.9% | ||||
| Site* | |||||||||
| Sun-protected | 196 (75.7%) | 53 | 27.0% | 1.00 (0.57–1.76) | 0.990 | 44 | 22.4% | 1.21 (0.68–2.14) | 0.515 |
| Sun-exposed | 63 (24.3%) | 16 | 25.4% | 16 | 25.4% | ||||
| Cytoplasmic Skp2 | |||||||||
| Low staining | 145 (56.0%) | 30 | 20.7% | 1.71 (1.07–2.76) | 0.027 | 25 | 17.2% | 1.84 (1.10–3.08) | 0.020 |
| High staining | 114 (44.0%) | 39 | 34.2% | 35 | 30.7% | ||||
| Nuclear Skp2 | |||||||||
| Low staining | 60 (23.2%) | 21 | 35.0% | 0.65 (0.39–1.09) | 0.100 | 19 | 31.7% | 0.62 (0.36–1.06) | 0.080 |
| High staining | 199 (76.8%) | 48 | 24.1% | 41 | 20.6% | ||||
*Sun-protected sites: trunk, arm, leg and feet; Sun-exposed sites: head and neck.
†
Log-Rank test. Abbreviations: HR, hazard ratio; CI, confidence interval.